All In Biotech

Free tool

FAERS Monitor: Yervoy

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 125377 or its brand name (Yervoy, Ipilimumab). Reports on generic versions are filed under their own applications.

Reports

43,846

Serious

38,953

89% of reports

Hospitalization

19,724

Death reported

9,828

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death4,577
  • malignant neoplasm progression3,853
  • diarrhoea3,159
  • off label use2,616
  • colitis2,337
  • pyrexia2,100
  • rash1,845
  • fatigue1,715
  • nausea1,401
  • intentional product use issue1,345
  • immune-mediated enterocolitis1,171
  • decreased appetite1,128
  • hypophysitis1,086
  • vomiting1,060
  • dyspnoea1,026

Reports by year received

View as table
YearReports
20065
20074
20086
200910
201020
2011571
20121,337
20131,115
20141,668
20152,030
20162,109
20173,406
20183,711
20194,250
20203,595
20214,090
20224,408
20233,218
20243,249
20252,534
20262,510

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,010,313 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hypophysitisSignal1,086561.4514.5279,518
immune-mediated enterocolitisSignal1,171223.6208.7176,791
colitisSignal2,33731.430.264,733
malignant neoplasm progressionSignal3,85318.718.162,463
intentional product use issueSignal1,3457.57.17,439
pyrexiaSignal2,1002.92.82,683
deathSignal4,5772.62.54,498
diarrhoeaSignal3,1592.42.32,525
decreased appetiteSignal1,1282.32.2866
rashSignal1,8452.01.9986
off label use2,6161.41.4358
vomiting1,0601.11.07
fatigue1,7151.11.05
dyspnoea1,0260.90.821
nausea1,4010.80.839

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.